Pfizer CEO and Chairman Albert Bourla on Tuesday announced that the company and its partner BioNTech have submitted a request to the U.S. Food and Drug Administration (FDA) seeking to expand authorization for its COVID-19 booster shot for use in 16- and 17-year-olds. It comes after U.S. regulators last week expanded the eligibility for a booster dose of Pfizer and BioNTech’s COVID-19 vaccine to all adults 18 and over, to be administered at least six months after receiving the second shot. If approved, the shot would be the first COVID-19 booster available to people under 18. Bourla, in announcing the move in a statement on Twitter, cited uncertainty surrounding the Omicron variant of the CCP (Chinese Communist Party) virus. President Joe Biden on Monday called the variant “a cause for concern, not a cause for panic.” “It is our hope to provide strong protection for as many people as possible, …